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■ EDITORIALS Clinical Medicine 2011, Vol 11, No 1: 8–10
The major forms of chronic inflammatory
bowel disease (IBD), Crohn’s disease (CD) and
ulcerative colitis (UC) are characterised by
inflammation of the intestinal tract. These
complex, lifelong conditions can present at any
age with peak incidences in the second and
third decades. The natural history of IBD
varies worldwide,1 with gradients in incidence,
phenotype and recurrence having been
demonstrated in Europe and North
America.2,3 The exact aetiological factors
involved in IBD pathogenesis remain elusive,
however it is becoming clear that genetic pre-
disposition, environmental influences and a
dysregulated immune response to the
intestinal microflora are involved.4–6
Since the first description of Crohn’s disease
in the early 20th century there have been sev-
eral lines of epidemiological evidence impli-
cating genetic susceptibility in the pathogen-
esis of IBD.7,8 The most notable of these
include the familial clustering of IBD cases, ethic differences in
disease susceptibility and high concordance rates in twins.9–11
The observation of increased twin concordance was demon-
strated in the late 1980s from large studies carried out in
Scandinavia and the UK.12 These studies showed that the risk of
CD in monozygotic twins is 36% and for UC 16%, in contrast to
4% for both diseases in dizygotic twins.13
Following this strong evidence for heritable factors non-para-
metric linkage analysis was employed to further delineate pos-
sible genes causing IBD susceptibility in the 1990s (Fig 1).13
Linkage analysis involves the study of a limited set of genetic
markers across the entire genome and does not explicitly specify
the mode of inheritance, looking instead for excessive allele
sharing in affected relatives. This method of gene identification
has come under scrutiny in recent years, mainly due to newer
techniques failing to replicate findings in these early analyses.
However, it should be noted that the gene identified in these
studies (NOD2/CARD15) remains the strongest individual
signal using genome-wide association scanning (GWAS).4
Without a doubt the major breakthrough in not only IBD
genetics but complex polygenic disease as a whole was the discovery
of NOD2/CARD15 in 1996. This gene was discovered by the French
paediatric gastroenterologist Hugot following fine mapping of the
IBD1 locus.15 Hugot’s group later identified variants in the leucine-
rich repeat region (LRR) of the gene as conferring susceptibility to
IBD, something which has been widely replicated in both adult and
early-onset disease.16,17 The gene encoded by NOD2/CARD15 has
gut expression limited to anti-microbial Paneth cells, with the LRR
domain recognising muramyl dipeptide (MDP), a product of bacte-
rial cell wall degradation.18,19 Since these initial studies, however, fur-
ther work has demonstrated a wide range of functions for this pat-
tern recognition receptor including the regulation of commensal
bacteria, the control of certain immune cell populations and viral
recognition.20–22
In more recent years the introduction of the Human Genome
Project and other international collaborations has allowed the
detailed examination of the entire genetic code.23 This informa-
tion, coupled with the creation of high-throughput genotyping
platforms, has led to the ability to analyse up to 500,000 single
nucleotide polymorphisms (SNPs) using hypothesis-free
GWAS. To date there have been a total of 14 GWAS performed
in IBD patients leading to an explosion of multiple candidate
genes implicated in IBD pathogenesis.17,24 Before the first major
CD meta-analysis published in 2008 by Barrett and colleagues,
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Fig 1. Timeline of epidemiological and genetic discoveries in inflammatory bowel disease.
CD  Crohn’s disease; GWAS  genome-wide association scan; IBD  inflammatory bowel
disease; UC  ulcerative colitis.
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only 16 loci had been identified, with the meta-analysis con-
firming many of these and providing evidence for 21 additional
SNPs.25,26 This has been expanded further still through recent
work by the International IBD Genetics Consortium with the
confirmed loci now numbering 69 in CD alone.24 Although
these identified loci will undoubtedly generate decades of future
research, it is postulated that they still only represent approxi-
mately 25% of the genetic variance, with only the option of deep
sequencing and functional studies likely to increase under-
standing of these susceptibility loci. What has become very clear,
however, is that the genetic architecture exposed by these scans
has led to a clearer understanding of the disease pathways and
mechanisms involved in IBD.
This insight provided by GWAS has uncovered candidate
genes involved in pathways broadly involving the control of
intestinal barrier function, the mucosal response to luminal bac-
teria and the secondary downstream immune response (Fig 2).
Besides NOD2/CARD15, the two pathways generating the most
interest at present are autophagy (the degradation of unwanted
cell organelles and the elimination of pathogenic microorgan-
isms) and the IL12–IL23 pathway (involved in pathogenic T cell
differentiation).11 SNPs in the regions of the autophagy genes
ATG16L1 and IRGM have been widely replicated as conferring
susceptibility to CD, with functional work beginning to unravel
the functional implications of their encoded proteins.27 The
association with CD of a germline variation of the IL23R (inter-
leukin-23 receptor) gene in 2006 provided the initial stimulus to
look more closely at the IL17-producing subset of CD4 Th17
cells.28 Since then risk and protective haplotypes of IL23R have
been described with other genes in the Th17 pathway, such as
STAT3, JAK2 and ICOSLG also implicated. In addition, the
exciting recent discovery that bacterial han-
dling and MHC class-II presentation are regu-
lated by NOD2 autophagy induction through
ATG16L1 has ignited the drive to establish a
cohesive model of disease pathogenesis.29,30
Not only has the study of genetics led to
advances in the understanding of IBD
aetiopathogenesis it has also enabled
researchers to focus on key areas of potential
therapeutic targets. Although gene therapy is
unlikely to play a part in IBD management in
the near future, several lines of pharmaceutical
intervention have already been highlighted
from gene discovery. The targeting of the IL12-
IL23 pathway has already shown promise with
the use of anti-p40 monoclonal antibody for
induction of remission in CD.31 Additionally,
the use of Sirolimus (which alters cellular
autophagy) has been shown to be of use in
refractory IBD and in the treatment of experi-
mentally-induced murine colitis.32,33 Although
specific drug treatments are still under devel-
opment, genotype analysis has already been
shown to inform clinicians regarding the nat-
ural history of IBD and in predicting treatment response to
newer biological drugs.34,35 It is hoped that in the coming years
the combination of genotyping, biomarkers and detailed pheno-
typing will allow a tailored approach to clinical management
using a validated predictive model.
It can be seen that IBD genetics has come a long way in a
short space of time, from twin studies to a clinical tool in less
than 30 years. Although there is still a great deal to be learned,
gaining unprecedented insight into complex polygenic disease
pathophysiology will no doubt lead to rapid discoveries not
only in IBD but other similar diseases. Within IBD research
there is now a pressing need to explore the gene-environmental
interactions especially with relation to CD-associated
adherent-invasive Escherichia coli, mycobacterium and ciga-
rette smoke.36–38 These interactions, in addition to the deep
sequencing of the candidate genes to unlock the disease-
causing mutations, will hopefully lead us even further towards
a panacea for this debilitating disease.
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